Management of glioblastoma in elderly patients
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolv...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Young, Jacob S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: A new global analytical potential energy surface of NaH - Yuan, Meiling ELSEVIER, 2018, official journal of the World Federation of Neurology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:380 ; year:2017 ; day:15 ; month:09 ; pages:250-255 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jns.2017.07.048 |
|---|
| Katalog-ID: |
ELV015539229 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV015539229 | ||
| 003 | DE-627 | ||
| 005 | 20230625115244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2017.07.048 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000268A.pica |
| 035 | |a (DE-627)ELV015539229 | ||
| 035 | |a (ELSEVIER)S0022-510X(17)30482-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.10 |2 bkl | ||
| 100 | 1 | |a Young, Jacob S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of glioblastoma in elderly patients |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. | ||
| 520 | |a Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. | ||
| 700 | 1 | |a Chmura, Steven J. |4 oth | |
| 700 | 1 | |a Wainwright, Derek A. |4 oth | |
| 700 | 1 | |a Yamini, Bakhtiar |4 oth | |
| 700 | 1 | |a Peters, Katherine B. |4 oth | |
| 700 | 1 | |a Lukas, Rimas V. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Yuan, Meiling ELSEVIER |t A new global analytical potential energy surface of NaH |d 2018 |d official journal of the World Federation of Neurology |g Amsterdam [u.a.] |w (DE-627)ELV001315870 |
| 773 | 1 | 8 | |g volume:380 |g year:2017 |g day:15 |g month:09 |g pages:250-255 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jns.2017.07.048 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.10 |j Physikalische Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 380 |j 2017 |b 15 |c 0915 |h 250-255 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j s y js jsy |
|---|---|
| matchkey_str |
youngjacobschmurastevenjwainwrightdereka:2017----:aaeetflolsoanle |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
35.10 |
| publishDate |
2017 |
| allfields |
10.1016/j.jns.2017.07.048 doi GBV00000000000268A.pica (DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.10 bkl Young, Jacob S. verfasserin aut Management of glioblastoma in elderly patients 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Chmura, Steven J. oth Wainwright, Derek A. oth Yamini, Bakhtiar oth Peters, Katherine B. oth Lukas, Rimas V. oth Enthalten in Elsevier Science Yuan, Meiling ELSEVIER A new global analytical potential energy surface of NaH 2018 official journal of the World Federation of Neurology Amsterdam [u.a.] (DE-627)ELV001315870 volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 https://doi.org/10.1016/j.jns.2017.07.048 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 380 2017 15 0915 250-255 6 045F 610 |
| spelling |
10.1016/j.jns.2017.07.048 doi GBV00000000000268A.pica (DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.10 bkl Young, Jacob S. verfasserin aut Management of glioblastoma in elderly patients 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Chmura, Steven J. oth Wainwright, Derek A. oth Yamini, Bakhtiar oth Peters, Katherine B. oth Lukas, Rimas V. oth Enthalten in Elsevier Science Yuan, Meiling ELSEVIER A new global analytical potential energy surface of NaH 2018 official journal of the World Federation of Neurology Amsterdam [u.a.] (DE-627)ELV001315870 volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 https://doi.org/10.1016/j.jns.2017.07.048 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 380 2017 15 0915 250-255 6 045F 610 |
| allfields_unstemmed |
10.1016/j.jns.2017.07.048 doi GBV00000000000268A.pica (DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.10 bkl Young, Jacob S. verfasserin aut Management of glioblastoma in elderly patients 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Chmura, Steven J. oth Wainwright, Derek A. oth Yamini, Bakhtiar oth Peters, Katherine B. oth Lukas, Rimas V. oth Enthalten in Elsevier Science Yuan, Meiling ELSEVIER A new global analytical potential energy surface of NaH 2018 official journal of the World Federation of Neurology Amsterdam [u.a.] (DE-627)ELV001315870 volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 https://doi.org/10.1016/j.jns.2017.07.048 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 380 2017 15 0915 250-255 6 045F 610 |
| allfieldsGer |
10.1016/j.jns.2017.07.048 doi GBV00000000000268A.pica (DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.10 bkl Young, Jacob S. verfasserin aut Management of glioblastoma in elderly patients 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Chmura, Steven J. oth Wainwright, Derek A. oth Yamini, Bakhtiar oth Peters, Katherine B. oth Lukas, Rimas V. oth Enthalten in Elsevier Science Yuan, Meiling ELSEVIER A new global analytical potential energy surface of NaH 2018 official journal of the World Federation of Neurology Amsterdam [u.a.] (DE-627)ELV001315870 volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 https://doi.org/10.1016/j.jns.2017.07.048 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 380 2017 15 0915 250-255 6 045F 610 |
| allfieldsSound |
10.1016/j.jns.2017.07.048 doi GBV00000000000268A.pica (DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.10 bkl Young, Jacob S. verfasserin aut Management of glioblastoma in elderly patients 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. Chmura, Steven J. oth Wainwright, Derek A. oth Yamini, Bakhtiar oth Peters, Katherine B. oth Lukas, Rimas V. oth Enthalten in Elsevier Science Yuan, Meiling ELSEVIER A new global analytical potential energy surface of NaH 2018 official journal of the World Federation of Neurology Amsterdam [u.a.] (DE-627)ELV001315870 volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 https://doi.org/10.1016/j.jns.2017.07.048 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 380 2017 15 0915 250-255 6 045F 610 |
| language |
English |
| source |
Enthalten in A new global analytical potential energy surface of NaH Amsterdam [u.a.] volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 |
| sourceStr |
Enthalten in A new global analytical potential energy surface of NaH Amsterdam [u.a.] volume:380 year:2017 day:15 month:09 pages:250-255 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Physikalische Chemie: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
A new global analytical potential energy surface of NaH |
| authorswithroles_txt_mv |
Young, Jacob S. @@aut@@ Chmura, Steven J. @@oth@@ Wainwright, Derek A. @@oth@@ Yamini, Bakhtiar @@oth@@ Peters, Katherine B. @@oth@@ Lukas, Rimas V. @@oth@@ |
| publishDateDaySort_date |
2017-01-15T00:00:00Z |
| hierarchy_top_id |
ELV001315870 |
| dewey-sort |
3610 |
| id |
ELV015539229 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015539229</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625115244.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jns.2017.07.048</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000268A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015539229</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-510X(17)30482-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Young, Jacob S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of glioblastoma in elderly patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chmura, Steven J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wainwright, Derek A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamini, Bakhtiar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peters, Katherine B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lukas, Rimas V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Yuan, Meiling ELSEVIER</subfield><subfield code="t">A new global analytical potential energy surface of NaH</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the World Federation of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001315870</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:380</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:15</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:250-255</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jns.2017.07.048</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">380</subfield><subfield code="j">2017</subfield><subfield code="b">15</subfield><subfield code="c">0915</subfield><subfield code="h">250-255</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Young, Jacob S. |
| spellingShingle |
Young, Jacob S. ddc 610 ddc 540 bkl 35.10 Management of glioblastoma in elderly patients |
| authorStr |
Young, Jacob S. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV001315870 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 35.10 bkl Management of glioblastoma in elderly patients |
| topic |
ddc 610 ddc 540 bkl 35.10 |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.10 |
| topic_browse |
ddc 610 ddc 540 bkl 35.10 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s j c sj sjc d a w da daw b y by k b p kb kbp r v l rv rvl |
| hierarchy_parent_title |
A new global analytical potential energy surface of NaH |
| hierarchy_parent_id |
ELV001315870 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
A new global analytical potential energy surface of NaH |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV001315870 |
| title |
Management of glioblastoma in elderly patients |
| ctrlnum |
(DE-627)ELV015539229 (ELSEVIER)S0022-510X(17)30482-3 |
| title_full |
Management of glioblastoma in elderly patients |
| author_sort |
Young, Jacob S. |
| journal |
A new global analytical potential energy surface of NaH |
| journalStr |
A new global analytical potential energy surface of NaH |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
250 |
| author_browse |
Young, Jacob S. |
| container_volume |
380 |
| physical |
6 |
| class |
610 610 DE-600 540 VZ 35.10 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Young, Jacob S. |
| doi_str_mv |
10.1016/j.jns.2017.07.048 |
| dewey-full |
610 540 |
| title_sort |
management of glioblastoma in elderly patients |
| title_auth |
Management of glioblastoma in elderly patients |
| abstract |
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. |
| abstractGer |
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. |
| abstract_unstemmed |
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Management of glioblastoma in elderly patients |
| url |
https://doi.org/10.1016/j.jns.2017.07.048 |
| remote_bool |
true |
| author2 |
Chmura, Steven J. Wainwright, Derek A. Yamini, Bakhtiar Peters, Katherine B. Lukas, Rimas V. |
| author2Str |
Chmura, Steven J. Wainwright, Derek A. Yamini, Bakhtiar Peters, Katherine B. Lukas, Rimas V. |
| ppnlink |
ELV001315870 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.jns.2017.07.048 |
| up_date |
2024-07-06T17:56:42.660Z |
| _version_ |
1803853341823860736 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015539229</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625115244.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jns.2017.07.048</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000268A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015539229</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-510X(17)30482-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Young, Jacob S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of glioblastoma in elderly patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chmura, Steven J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wainwright, Derek A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamini, Bakhtiar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peters, Katherine B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lukas, Rimas V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Yuan, Meiling ELSEVIER</subfield><subfield code="t">A new global analytical potential energy surface of NaH</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the World Federation of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001315870</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:380</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:15</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:250-255</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jns.2017.07.048</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">380</subfield><subfield code="j">2017</subfield><subfield code="b">15</subfield><subfield code="c">0915</subfield><subfield code="h">250-255</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4001637 |